2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3H-purin-6-one | 125962-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3H-purin-6-one
• 英文别名: 9-guanine；2-amino-9-(cis-3-(hydroxymethyl)cyclobutyl)-1,9-dihydro-6H-purin-6-one；9-[(1β,3β)-3-hydroxymethylcyclobutan-1-yl]guanine
• CAS: 125962-37-0
• 化学式: C₁₀H₁₃N₅O₂
• 分子量: 235.246
• InChiKey: UMHYNECKSWGZMS-OLQVQODUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.35
• 重原子数：
  17.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  109.82
• 氢给体数：
  3.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3H-purin-6-one 在 磷酸三乙酯 、 N,N'-羰基二咪唑 、 三氯氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 51.5h， 生成 (cis-3-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)cyclobutyl)methyl tetrahydrogentriphosphate
  参考文献：
  名称：

  Synthetic Nucleosides and Nucleotides. 43. Inhibition of Vertebrate Telomerases by Carbocyclic Oxetanocin G (C.OXT-G) Triphosphate Analogues and Influence of C.OXT-G Treatment on Telomere Length in Human HL60 Cells

  摘要：

  Telomerase, responsible for telomere synthesis, is expressed in greater than or similar to 90% of human tumor cells but seldom in normal somatic cells. In this study, inhibition by carbocyclic oxetanocin G triphosphate (C.OXT-GTP) and its analogues was investigated in order to clarify the susceptibility of telomerase to various nucleotide analogues. C.OXT-GTP competitively inhibited telomerase activity with respect to dGTP. However, C.OXT-GTP had a potent inhibitory effect on DNA polymerase alpha. It was examined whether the nucleoside (C.OXT-G) was able to alter telomere length in cultured human HL60 cells. Contrary to expectation, long-term treatment with 10 mu M C.OXT-G was found to cause telomere lengthening.

  DOI：

  10.1080/15257770600684217
• 作为产物：
  描述：

  3-(benzyloxymethyl)-2,2-dichlorocyclobutanone 在 1,1,2,3-四甲基胍 、 三氯化硼 、 L-Selectride 、 溶剂黄146 、 二乙酰一肟 、 间氯过氧苯甲酸 、 三苯基膦 、 甲胺 、 锌 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 37.08h， 生成 2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3H-purin-6-one
  参考文献：
  名称：

  Synthesis of 9-[cis-3-(hydroxymethyl)cyclobutyl]-adenine and -guanine

  摘要：

  2,2-Dichloro-3-(benzyloxymethyl)cyclobutanone 15, which was prepared in 50% yield by the cycloaddition of dichloroketene to allyl benzyl ether 14, was converted in four steps and in similar to 40% overall yield into trans-3-(benzyloxymethyl)cyclobutanol 11b. The latter alcohol 11b was coupled under Mitsunobu conditions with 6-(4-chlorophenylsulfanyl)-9H-purine 21b and 6-(4-chlorophenylsulfanyl)-2-(phenylacetamido)-9H-purine 21c to give the 9-cyclobutylpurine derivatives 22 and 24, respectively, in 88 and 60% yield. The former product 22 was converted in three steps and in 39% overall yield into 9-[cis-3-(hydroxymethyl)cyclobutyl]adenine 6, and the latter product was converted in four steps and in 42% overall yield into 9-[cis-3-(hydroxymethyl)cyclobutyl] guanine 7. X-Ray crystallographic data relating to compounds 22 and 24 are also reported.

  DOI：

  10.1039/p19950002281

文献信息

• CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF
  申请人：Fujifilm Corporation

  公开号：US20210155644A1

  公开（公告）日：2021-05-27

  An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides an anti-adenoviral agent including a compound represented by General Formula [1] (in the formula, R 1 represents a hydrogen atom, a halogen atom, an amino group which may be substituted, a monocyclic nitrogen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a monocyclic nitrogen- and oxygen-containing heterocyclic ring group which may be substituted (provided that a nitrogen atom forming the ring is bonded to a carbon atom to which R 1 is bonded), a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; and X represents an oxygen atom or a sulfur atom) or a salt thereof.

  本发明的一个目的是提供一种作为抗腺病毒药剂具有优异药效的化合物，以及一种抗腺病毒药剂。本发明提供了一种包括由通式[1]表示的化合物的抗腺病毒药剂 （在公式中，R 1 表示氢原子、卤素原子、可能被取代的氨基、可能被取代的单环氮含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的单环氮和氧含杂环基团（前提是形成环的氮原子与R 1 结合的碳原子相结合）、可能被取代的C 1-6 烷氧基、可能被保护的羟基等；R 2 表示氢原子或氨基保护基团；R 3 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；R 4 表示可能被取代的C 1-20 烷氧基、可能被取代的芳氧基、可能被取代的氨基等；X表示氧原子或硫原子）或其盐。
• CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF
  申请人：FUJIFILM Corporation

  公开号：US20210147456A1

  公开（公告）日：2021-05-20

  An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R 1 represents a halogen atom, an amino group which may be substituted, a C 1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R 2 represents a hydrogen atom or an amino protecting group; R 3 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R 4 represents a C 1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.

  本发明的一个目的是提供一种作为抗腺病毒药剂的化合物，以及一种抗腺病毒药剂。本发明提供一种由通式[1]表示的化合物 （在该式中，R 1 代表卤原子，可能被取代的氨基，可能被取代的C 1-6 烷氧基，可能被保护的羟基等；R 2 代表氢原子或氨基保护基；R 3 代表可能被取代的C 1-20 烷氧基，可能被取代的芳氧基，可能被取代的氨基等；R 4 代表可能被取代的C 1-20 烷氧基，可能被取代的芳氧基，可能被取代的氨基等）；或其盐。
• Synthesis and antiviral activities of carbocyclic oxetanocin analogues.
  作者：Tokumi MARUYAMA、Yoshiko SATO、Takahiko HORII、Hiroshi SHIOTA、Keiko NITTA、Takuma SHIRASAKA、Hiroaki MITSUYA、Mikio HONJO

  DOI：10.1248/cpb.38.2719

  日期：——

  cyclobutyl]adenine(4d) were prepared from the corresponding cyclobutylamine derivatives (1a, 1b and 1d). Guanine congeners (9a, cis- and trans-9b and 9d) and carbocyclic oxetanocin G (1',2'-trans-9f) were also prepared. Carbocyclic oxetanocin A(1',2'-trans-4f), the preparation of which we have already published, and G were found to be active against herpes simplex virus (type 1 and 2) in vitro, while

  由相应的环丁胺制备9-环丁基腺嘌呤（4a），顺式和反式9- [3-（羟甲基）环丁基]腺嘌呤（4b）和9- [3,3-双（羟甲基）环丁基]腺嘌呤（4d）。导数（1a，1b和1d）。还制备了鸟嘌呤同源物（9a，顺式和反式9b和9d）和碳环氧杂环丁霉素G（1'，2'-trans-9f）。我们已经公开了碳氧杂环丁烷素A（1'，2'-trans-4f）和G在体外对单纯疱疹病毒（1型和2型）具有活性，而cis-4b和cis具有活性。 -9b显示了针对人类免疫缺陷病毒（1型）的体外抗逆转录病毒活性。
• Hydroxymethyl cyclobutyl purines
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US05369098A1

  公开（公告）日：1994-11-29

  Antiviral activity is exhibited by compounds having the formula ##STR1## and their pharmaceutically acceptable salts. R.sub.1 is ##STR2## R.sub.2 is hydrogen, --PO.sub.3 H.sub.2, ##STR3## wherein R.sub.3 is hydrogen, alkyl, substituted alkyl, or aryl, and R.sub.4 is alkyl.

  具有以下式子 ##STR1## 及其药学上可接受的盐的化合物表现出抗病毒活性。其中，R.sub.1是 ##STR2## R.sub.2是氢，--PO.sub.3 H.sub.2，##STR3## 其中R.sub.3是氢、烷基、取代烷基或芳基，R.sub.4是烷基。
• 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation
  申请人：Liotta Dennis C.

  公开号：US20090149416A1

  公开（公告）日：2009-06-11

  Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.

  提供了环丁基核苷和它们的使用方法，用于治疗感染，包括逆转录病毒科（包括HIV），乙肝病毒科（包括HBV）或黄病毒科（包括BVDV和HCV）感染，或与异常细胞增殖有关的情况，在宿主中使用，包括动物，尤其是人类。